Product Information
POTASSIUM CL ER 8 MEQ CAPSULE is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $0.1160 per EA under NDC 68180079801. Its NADAC has been published 526 times since Mar 9, 2016.
FDA first approved this application on Dec 18, 2015.
Strength
8 meq/1
Manufacturer
Lupin Pharmaceuticals Inc.NDC
68180079801
Classification
Generic
Dosage Form
CAPSULE, COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
3/18/2026
Active Ingredients
POTASSIUM CHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA203002FDA Approved
12/18/2015
On Market Since
1/18/2016
Pharmacological Classes
Price Statistics
The NADAC for POTASSIUM CL ER 8 MEQ CAPSULE has been published 526 times since Mar 9, 2016, and over the history we have for it it has declined 75.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1160 per EA |
|---|---|
| All-time high | $0.6513 (Aug 10, 2016) |
| All-time low | $0.1094 (Apr 17, 2024) |
| 52-week high | $0.1336 |
| 52-week low | $0.1160 |
| Median price | $0.2533 |
| Average price | $0.2640 |
| Largest weekly change | +73.8% (Apr 18, 2018) |
| Weeks tracked | 526 |
| Tracking since | Mar 9, 2016 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
-13.2%
3Y
-32.0%
5Y
-35.6%
All
-75.2%
Last surveyed Apr 1, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Potassium Chloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Potassium Chloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Osmotic Laxative class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of POTASSIUM CL ER 8 MEQ CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for POTASSIUM CL ER 8 MEQ CAPSULE, manufactured by Lupin Pharmaceuticals Inc., is $0.1160 per EA (NDC 68180079801), effective Apr 1, 2026.
How has the price of POTASSIUM CL ER 8 MEQ CAPSULE changed over time?
Over the history we have for it, the NADAC for POTASSIUM CL ER 8 MEQ CAPSULE has declined 75.2%. It has been tracked across 526 weekly CMS publications since Mar 9, 2016.
What are the highest and lowest recorded NADAC prices for POTASSIUM CL ER 8 MEQ CAPSULE?
Since Mar 9, 2016, the NADAC for POTASSIUM CL ER 8 MEQ CAPSULE has ranged from a low of $0.1094 (Apr 17, 2024) to a high of $0.6513 (Aug 10, 2016), with a median of $0.2533 per EA.
Are there cheaper alternatives to POTASSIUM CL ER 8 MEQ CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of POTASSIUM CL ER 8 MEQ CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures POTASSIUM CL ER 8 MEQ CAPSULE?
POTASSIUM CL ER 8 MEQ CAPSULE (NDC 68180079801) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.